An integrated therapeutic approach to sickle cell disease management beyond infancy

Abstract

AbstractHydroxyurea, the first approved drug for sickle cell disease, decreases sickle hemoglobin polymerization by inducing fetal hemoglobin. Its effects in young children are excellent; responses in adults are variable and not curative. The goal of pharmacotherapy should not be disease “moderation” but reducing morbidity and mortality by diminishing both hemolytic anemia and vaso‐occlusive events. This is best done by preventing sickle hemoglobin polymerization; if anti‐polymerization treatment is insufficient, agents disrupting pathophysiologic pathways “downstream” of the sickle hemoglobin polymer should be added. We recommend that all patients should be started first on maximal doses of hydroxyurea. When the clinical and hematologic response to hydroxyurea is insufficient, as it is almost always in adults, we favor adding voxelotor, a hemoglobin‐oxygen affinity‐shifting agent that, likely in a pancellular distribution, decreases sickle hemoglobin polymerization. The P‐selectin inhibitor crizanlizumab reduces sickle cell‐endothelial interactions and can be used in patients with continued vaso‐occlusive events. There is no physiologic reason that all three drugs could not be combined when the response to monotherapy or dual‐drug therapy is poor. Drug therapy must be considered in the context of possibly “curative” cellular therapeutics and if needed, exchange transfusion programs.